Patents by Inventor Michael John Rodriguez

Michael John Rodriguez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRas inhibitors
    Patent number: 12351591
    Abstract: The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
    Type: Grant
    Filed: March 24, 2023
    Date of Patent: July 8, 2025
    Assignee: ELI LILLY AND COMPANY
    Inventors: David Anthony Barda, Jolie Anne Bastian, Kelly Wayne Furness, Deqi Guo, James Robert Henry, Richard Duane Johnston, Jason Eric Lamar, Tao Liu, Michael John Rodriguez, Almudena Rubio, Chong Si, Gaiying Zhao, Mohammad Sadegh Zia-Ebrahimi, Matthew Patrick Baumgartner, Isabel Rojo, Mario Barberis, Santiago Carballares Martin, Pablo Garcia Losada, Sonia Maria Gutierrez Sanfeliciano, Wenceslao Lumeras Amador, Victoriano Molero Florez, Maria Lourdes Prieto Vallejo
  • KRAS INHIBITORS
    Publication number: 20240043451
    Abstract: The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
    Type: Application
    Filed: March 24, 2023
    Publication date: February 8, 2024
    Inventors: David Anthony BARDA, Jolie Anne BASTIAN, Kelly Wayne FURNESS, Deqi GUO, James Robert HENRY, Richard Duane JOHNSTON, Jason Eric LAMAR, Tao LIU, Michael John RODRIGUEZ, Almudena RUBIO, Chong SI, Gaiying ZHAO, Mohammad Sadegh ZIA-EBRAHIMI, Matthew Patrick BAUMGARTNER, Isabel ROJO, Mario BARBERIS, Santiago CARBALLARES MARTIN, Pablo GARCIA LOSADA, Sonia Maria GUTIERREZ SANFELICIANO, Wenceslao LUMERAS AMADOR, Victoriano MOLERO FLOREZ, Maria Lourdes PRIETO VALLEJO
  • ERK inhibitors
    Patent number: 9879029
    Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: January 30, 2018
    Assignee: Eli Lilly and Company
    Inventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William Thomas McMillen, Michael John Rodriguez, Gaiying Zhao
  • ERK INHIBITORS
    Publication number: 20170267691
    Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
    Type: Application
    Filed: December 15, 2015
    Publication date: September 21, 2017
    Inventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William Thomas McMillen, Michael John Rodriguez, Gaiying Zhao
  • INHIBITORS OF EZH2
    Publication number: 20170066780
    Abstract: The present invention relates to compounds that inhibit activity of the histone lysine methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors.
    Type: Application
    Filed: August 22, 2016
    Publication date: March 9, 2017
    Inventors: Esteban DOMINGUEZ, Deqi GUO, Mary Margaret MADER, Anh-Quan Hannah NGUYEN, Miriam DEL PRADO, Michael Enrico RICHETT, Michael John RODRIGUEZ, Yvonne Yee Mai YIP, Kuo-Long YU
  • ERK inhibitors
    Patent number: 9469652
    Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: October 18, 2016
    Assignee: Eli Lilly and Company
    Inventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William T. McMillen, Michael John Rodriguez, Gaiying Zhao
  • ERK INHIBITORS
    Publication number: 20160176896
    Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 23, 2016
    Inventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William T. McMillen, Michael John Rodriguez, Gaiying Zhao
  • 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonist
    Patent number: 8580780
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: November 12, 2013
    Assignee: Eli Lilly and Company
    Inventors: John Gordon Allen, Karin Briner, Christopher Stanley Galka, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothhaar, Michael Wade Tidwell, Frantz Victor, Deyi Zhang, Steven Armen Boyd, Arundhati S. Deo, Wai-Man Lee, Christopher Stephen Siedem, Ajay Singh
  • 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist
    Publication number: 20120028961
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.
    Type: Application
    Filed: July 28, 2011
    Publication date: February 2, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: JOHN GORDON ALLEN, Karin Briner, Michael Philip Cohen, Christopher Stanley Galka, Sarah Lynne Hellman, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothhaar, Michael Wade Tidwell, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang, Steven Armen Boyd, Richard Gerard Conway, Arundhati S. Deo, Wai-Man Lee, Christopher Stephen Siedem, Ajay Singh, Michael Philip MAZANETZ
  • 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonists
    Patent number: 8022062
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —C?C—R10, —O—R12, —S—R14, or —NR24R25; and other substituents are as defined in the specification.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: September 20, 2011
    Assignee: Eli Lilly and Company
    Inventors: John Gordon Allen, Karin Briner, Michael Philip Cohen, Christopher Stanley Galka, Sarah Lynne Hellman, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothhaar, Michael Wade Tidwell, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang, Michael Philip Mazanetz
  • 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
    Publication number: 20090099155
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzoazepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is -C?C-R10, -O-R12, -S-R14, or -NR24R25; and other substituents are as defined in the specification.
    Type: Application
    Filed: September 9, 2005
    Publication date: April 16, 2009
    Inventors: John Gordon Allen, Karin Briner, Michael Philip Cohen, Christopher Stanley Galka, Sarah Lynne Hellman, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothaar, Michael Wade Tidwell, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang, Steven Armen Boyd, Richard Gerard Conway, Arundhati S. Deo, Wai-Man Lee, Christopher Stephen Siedem, Ajay Singh, Michael Philip Mazanetz
  • Cyclic peptide antifungal agents
    Publication number: 20030125240
    Abstract: The present invention relates to compounds of formula I: 1
    Type: Application
    Filed: August 30, 2001
    Publication date: July 3, 2003
    Inventors: James Andrew Jamison, Michael John Rodriguez, Venkatraghavan Vasudevan
  • Cyclic peptide antifungal agents
    Patent number: 6323176
    Abstract: The present invention relates to compounds of formula where R5 is a sugar moiety. The compounds are useful in inhibiting fungal and parasitic activity and infections.
    Type: Grant
    Filed: February 5, 1999
    Date of Patent: November 27, 2001
    Assignee: Eli Lilly and Company
    Inventors: James Andrew Jamison, Michael John Rodriguez, Venkatraghavan Vasudevan
  • Amides
    Patent number: 5919756
    Abstract: The present invention is directed to amides of antibiotic A82846B (also known as chloroorienticin A), and of N.sup.4 -derivatives of A82846B. The present amide compounds are useful as antibacterials, especially for the control of gram positive bacteria; the compounds are particularly useful for the control of resistant bacterial strains, such as vancomycin-resistant-enterococci ("VRE").
    Type: Grant
    Filed: May 1, 1997
    Date of Patent: July 6, 1999
    Assignee: Eli Lilly and Company
    Inventors: Robin David Grey Cooper, Michael John Rodriguez, Nancy June Snyder, Mark James Zweifel
  • ERK inhibitors
    Patent number: RE48635
    Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: July 13, 2021
    Assignee: Eli Lilly and Company
    Inventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William T. McMillen, Michael John Rodriguez, Gaiying Zhao